Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.41 |
| ▸ | PPARA | Q07869 | 11/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31333868 | 0.92 | PPARD (0.39) | PPARDPPARAPPARGHPGDALDH1A1 | |
| SCHEMBL31333728 | 0.91 | PPARD (0.43) | PPARDPPARAPPARGHPGDALDH1A1 | |
| SCHEMBL30579924 | 0.91 | PPARD (0.46) | PPARDPPARAPPARGHPGDALDH1A1 | |
| SCHEMBL25398941 | 0.91 | PPARD (0.46) | PPARDPPARAPPARGHPGDALDH1A1 | |
| SCHEMBL30579913 | 0.91 | PPARD (0.53) | PPARDPPARAPPARGHPGDALDH1A1 | |
| SCHEMBL25397774 | 0.91 | PPARD (0.53) | PPARDPPARAPPARGHPGDALDH1A1 | |
| SCHEMBL25396403 | 0.89 | KDM4E (0.43) | PPARDPPARAPPARGHPGDALDH1A1 | |
| SCHEMBL31333786 | 0.85 | PPARD (0.49) | PPARDPPARAPPARG | |
| SCHEMBL25398468 | 0.83 | TSHR (0.45) | PPARDPPARAPPARGHPGDALDH1A1 | |
| SCHEMBL31333820 | 0.83 | PPARD (0.49) | PPARDPPARAPPARGHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197363-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | CUREVERSE INCORPORATED (KR) | 2025-06-19 | — | — | US | disclosed |
| EP-4495106-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2025-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197363-A1 | THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME | PPARD, PPARG, PPARA | PPARD 1/4885PPARA 3/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.